Evidence map›Paper›PMID 35546239›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.

Runzhe Chen, Jun Li, Junya Fujimoto, Lingzhi Hong, Xin Hu, Kelly Quek, Ming Tang, Akash Mitra, Carmen Behrens, Chi-Wan Chow and 13 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024
    Article
  4. T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 1 institution in 2 countries.

Runzhe Chen *Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jun Li *Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Junya FujimotoDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Lingzhi HongDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Xin HuDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Kelly QuekDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ming TangDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Akash MitraDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Carmen BehrensDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Chi-Wan ChowDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Peixin JiangDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Latasha D LittleDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Curtis GumbsDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Xingzhi SongDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jianhua ZhangDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Dongfeng TanDepartment of Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ignacio WistubaDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
P Andrew FutrealDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Don L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. dlgibbon@mdanderson.org.
Lauren A ByersDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. lbyers@mdanderson.org.
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org.
Alexandre ReubenDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. areuben@mdanderson.org.ORCID http://orcid.org/0000-0003-4510-0382
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundLung cancer is the leading cause of cancer death, partially owing to its extensive heterogeneity. The analysis of intertumor heterogeneity has been limited by an inability to concurrently obtain tissue from synchronous metastases unaltered by multiple prior lines of therapy.

methodsIn order to study the relationship between genomic, epigenomic and T cell repertoire heterogeneity in a rare autopsy case from a 32-year-old female never-smoker with left lung primary late-stage lung adenocarcinoma (LUAD), we did whole-exome sequencing (WES), DNA methylation and T cell receptor (TCR) sequencing to characterize the immunogenomic landscape of one primary and 19 synchronous metastatic tumors.

resultsWe observed heterogeneous mutation, methylation, and T cell patterns across distinct metastases. Only TP53 mutation was detected in all tumors suggesting an early event while other cancer gene mutations were later events which may have followed subclonal diversification. A set of prevalent T cell clonotypes were completely excluded from left-side thoracic tumors indicating distinct T cell repertoire profiles between left-side and non left-side thoracic tumors. Though a limited number of predicted neoantigens were shared, these were associated with homology of the T cell repertoire across metastases. Lastly, ratio of methylated neoantigen coding mutations was negatively associated with T-cell density, richness and clonality, suggesting neoantigen methylation may partially drive immunosuppression.

conclusionsOur study demonstrates heterogeneous genomic and T cell profiles across synchronous metastases and how restriction of unique T cell clonotypes within an individual may differentially shape the genomic and epigenomic landscapes of synchronous lung metastases.

Indexed as

AdenocarcinomaAdenocarcinoma of LungLung NeoplasmsAdultExome SequencingFemaleHumansMutationGenomicIntertumor heterogeneityLung adenocarcinomaT cell repertoire

Identifiers

PMID35546239
PMCPMC9092788
OpenAlexW4280562829

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.